Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
CDH4 Biologics Sequence Review Report 2026: Cadherin-4 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CDH4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CDON Biologics Sequence Review Report 2026: Cell adhesion molecule-related/down-regulated by oncogenes Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CDON protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CDHR2 Biologics Sequence Review Report 2026: Cadherin-related family member 2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CDHR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD163L1 Biologics Sequence Review Report 2026: Scavenger receptor cysteine-rich type 1 protein M160 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CD163L1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CDH2 Biologics Sequence Review Report 2026: Cadherin-2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CDH2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD163 Biologics Sequence Review Report 2026: Scavenger receptor cysteine-rich type 1 protein M130 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CD163 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD109 Biologics Sequence Review Report 2026: CD109 antigen Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CD109 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
LRIF1 Biologics Sequence Review Report 2026: Ligand-dependent nuclear receptor-interacting factor 1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of LRIF1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
OGFR Biologics Sequence Review Report 2026: Opioid growth factor receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of OGFR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PIGR Biologics Sequence Review Report 2026: Polymeric immunoglobulin receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of PIGR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD101 Biologics Sequence Review Report 2026: Immunoglobulin superfamily member 2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CD101 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
LCORL Biologics Sequence Review Report 2026: Ligand-dependent nuclear receptor corepressor-like protein Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of LCORL protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
108
109
110
111
112
>>
1670
>